Section Arrow
CELC.NASDAQ
- Celcuity
Quotes are at least 15-min delayed:2026/02/23 19:04 EST
After Hours
Last
 105.15
0 (0.00%)
Bid
105.04
Ask
105.25
High 106.38 
Low 105.15 
Volume 73.41K 
Regular Hours (Closed)
Last
 105.15
+0.36 (+0.34%)
Day High 
107.5 
Prev. Close
104.79 
1-M High
120.315 
Volume 
101 
Bid
105.04
Ask
105.25
Day Low
103.0001 
Open
104 
1-M Low
97.49 
Market Cap 
4.85B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 105.7 
20-SMA 108.43 
50-SMA 105.6 
52-W High 120.315 
52-W Low 7.575 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.68/0.65
Enterprise Value
4.95B
Balance Sheet
Book Value Per Share
2.53
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
GOSSGossamer Bio0.42055-1.70945-80.26%-- 
After Hours 0.4042 -0.01635 -3.89%
IBRXImmunityBio9.82+1.12+12.87%-- 
After Hours 9.83 +0.01 +0.10%
VNDAVanda Pharmaceuticals8.17+2.41+41.84%-- 
After Hours 8.2816 +0.1116 +1.37%
IKTInhibikase Therapeutics1.8+0.04+2.27%3.74PE
After Hours 1.82 +0.02 +1.11%
KLTOKlotho Neurosciences Inc0.41+0.1573+62.25%-- 
After Hours 0.3872 -0.0228 -5.56%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic propertiesare differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.